Effect of Low Dose of Hydroxyurea in SCD Children with Arab-Indian phenotype- Local Experience

Effect of Low Dose of Hydroxyurea in SCD Children with Arab-Indian phenotype- Local Experience

Bibliographic Details
Main Author:	Zahra Jaber Hussein
Format:	Article
Language:	English
Published:	Elsevier 2023-01-01
Series:	Journal of Taibah University Medical Sciences
Online Access:	http://www.sciencedirect.com/science/article/pii/S1658361223001786

Similar Items

The Role of Hydroxyurea on Growth in Children with SCD
by: Zahrah Mohammed Alkashi
Published: (2023-01-01)

Hydroxyurea utilization and dose optimization in children with sickle cell disease (SCD)
by: Nour Alotaibi, et al.
Published: (2023-01-01)

Outcome of Hydroxyurea Use in SCD and Evaluation of Patients’ Perception and Experience in Nigeria
by: Reuben Ikechukwu Chianumba, et al.
Published: (2022-03-01)

Hydroxyurea pharmacokinetics and precision dosing in low-resource settings
by: Luke R. Smart, et al.
Published: (2023-06-01)

O-12: BUILDING LOCAL CAPACITY FOR HYDROXYUREA PHARMACOKINETICS AND PRECISION DOSING IN LOW-RESOURCE SETTINGS
by: SMART L., et al.
Published: (2022-08-01)

Successful treatment of hydroxyurea-associated panniculitis and vasculitis with low-dose methotrexate
by: Sarah Mattessich, BS, et al.
Published: (2017-09-01)

Minimal doses of hydroxyurea for sickle cell disease
by: C.S.P. Lima, et al.
Published: (1997-08-01)

S269: MALE PATIENTS WITH SCD HAVE A HIGHER RISK OF CEREBROVASCULAR DISEASE, INCREASED INFLAMMATORY MARKERS, AND POORER RESPONSE TO HYDROXYUREA
by: Margherita DI Mauro, et al.
Published: (2023-08-01)

Moderate dose of hydroxyurea in children with sickle cell disease and stroke. Preliminary results
by: Sergio Machín-García, et al.

P-017: POINT-OF-CARE DIAGNOSTIC FOR QUANTIFICATION OF FOETAL HAEMOGLOBIN (HB F) LEVELS IN MONITORING HYDROXYUREA THERAPY FOR CHILDREN WITH SICKLE CELL DISEASE (SCD) IN GHANA
by: SEGBEFIA C., et al.
Published: (2022-08-01)

Therapeutic Dose of Hydroxyurea-Induced Synaptic Abnormalities on the Mouse Spermatocyte
by: Xiaobo Fan, et al.
Published: (2021-07-01)

5613426 LOW CHRONIC INFLAMMATION IN SCD
by: M.R. Rolli, et al.
Published: (2023-04-01)

A Scd1-mediated metabolic alteration participates in liver responses to low-dose bavachin
by: Pan Shen, et al.
Published: (2023-07-01)

Improvement of SCD morbimortality in children: experience in a remote area of an African country
by: Benoît Mukinayi Mbiya, et al.
Published: (2021-04-01)

P-075: HYDROXYUREA: EFFECTS ON TREATMENT OF CHILDREN WITH HEMOGLOBINOPATHY SC
by: CAMPOS A., et al.
Published: (2022-08-01)

P-042: POPULATION PHARMACOKINETICS AND PHARMACODYNAMICS ANALYSIS OF HYDROXYUREA, IN ADULT PATIENTS WITH SICKLE CELL DISEASE (SCD) RECEIVING BOTH TABLETS OR CAPSULES FORMULATIONS, AND EVALUATION OF DISEASE MARKERS
by: BARTOLUCCI P., et al.
Published: (2022-08-01)

Hydroxyurea granules for the management of sickle cell disease in children
by: Grace Lovia Allotey-Babington, et al.
Published: (2022-07-01)

Hydroxyurea-induced melanonychia
by: Michael G. Buontempo, BS, et al.
Published: (2023-12-01)

Qualitative Analysis of Hydroxyurea
by: Stéfanno Souza Santos, et al.
Published: (2020-07-01)

Qualitative Analysis of Hydroxyurea
by: Stéfanno Souza Santos, et al.
Published: (2020-07-01)

Qualitative Analysis of Hydroxyurea
by: Stéfanno Souza Santos, et al.
Published: (2020-07-01)

Qualitative Analysis of Hydroxyurea
by: Stéfanno Souza Santos, et al.
Published: (2020-07-01)

Sums of SCD sets and their applications to SCD operators and narrow operators
by: Kadets Vladimir, et al.
Published: (2010-02-01)

Barriers and Facilitators of Use of Hydroxyurea among Children with Sickle Cell Disease: Experiences of Stakeholders in Tanzania
by: Manase Kilonzi, et al.
Published: (2021-11-01)

Is Hydroxyurea Treatment Changing the Life of Children with Sickle Cell Disease?
by: Mohammed Ali Al Sabbah, et al.
Published: (2023-07-01)

Hydroxyurea—The Good, the Bad and the Ugly
by: Marcelina W. Musiałek, et al.
Published: (2021-07-01)

Hydroxyurea-induced Tooth Discoloration
by: Muhammed Okuyucu, et al.
Published: (2020-02-01)

Blue Lunula Related with Hydroxyurea
by: Hava Üsküdar Teke, et al.
Published: (2013-03-01)

Adherence to Hydroxyurea and Patients’ Perceptions of Sickle Cell Disease and Hydroxyurea: A Cross-Sectional Study
by: Mohammed Ali Madkhali, et al.
Published: (2024-01-01)

Systemic, but not local, low-grade endotoxinemia increases plasma sCD163 independently of the cortisol response
by: Ermina Bach, et al.
Published: (2019-02-01)

sCD163, sCD28, sCD80, and sCTLA-4 as soluble marker candidates for detecting immunosenescence
by: Andrea Aprilia, et al.
Published: (2024-01-01)

Effect of Hydroxyurea Treatment on the Inflammatory Markers Among Children With Sickle Cell Disease
by: Asmaa M. Zahran MD, et al.
Published: (2020-01-01)

Effectiveness of Pharmacokinetic-Guided Hydroxyurea Dose Individualization in Patients with Sickle Cell Anemia: A Mini-Review
by: Joelma Santana dos Santos Neres, et al.
Published: (2023-06-01)

THE ASSESSMENT OF CEREBROVASCULAR-DISEASE IN CHILDREN WITH SICKLE-CELL DISEASE (SCD)
by: Hewes, D, et al.
Published: (1993)

P1480: SPLENIC SEQUESTRATION IS MORE COMMON IN SCD-S/Β0-THAL THAN IN SCD-S/S PATIENTS: RESULTS FROM THE GERMAN SCD REGISTRY
by: P. Allard, et al.
Published: (2022-06-01)

Risk of classical Kaposi sarcoma by plasma levels of Epstein-Barr virus antibodies, sCD26, sCD23 and sCD30
by: Viviano Enza, et al.
Published: (2010-10-01)

The Use of Hydroxyurea in the Treatment of COVID-19
by: Foster Melissa Robin Bowman, et al.
Published: (2021-10-01)

Oral lesions associated with hydroxyurea treatment
by: Regina Mendonça, et al.
Published: (2011-01-01)

Evidence review of hydroxyurea for the prevention of sickle cell complications in low-income countries.
by: Mulaku, M, et al.
Published: (2013)

Evidence review of hydroxyurea for the prevention of sickle cell complications in low-income countries
by: Mulaku, M, et al.
Published: (2013)